KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Humana (HUM) Notes Payables (2016 - 2025)

Humana (HUM) has disclosed Notes Payables for 16 consecutive years, with $306.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Notes Payables changed N/A to $306.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $306.0 million, a N/A change, with the full-year FY2025 number at $306.0 million, changed N/A from a year prior.
  • Notes Payables was $306.0 million for Q4 2025 at Humana, down from $308.0 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $457.0 million in Q2 2023 to a low of $236.0 million in Q2 2021.
  • A 4-year average of $318.6 million and a median of $308.0 million in 2025 define the central range for Notes Payables.
  • Biggest YoY gain for Notes Payables was 102.96% in 2021; the steepest drop was 23.87% in 2021.
  • Humana's Notes Payables stood at $326.0 million in 2021, then dropped by 8.59% to $298.0 million in 2022, then fell by 17.45% to $246.0 million in 2023, then grew by 24.39% to $306.0 million in 2025.
  • Per Business Quant, the three most recent readings for HUM's Notes Payables are $306.0 million (Q4 2025), $308.0 million (Q3 2025), and $298.0 million (Q2 2025).